Who are LVRNA009's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mRNA-1273 Variant-containing Formulation, COVID-19 mRNA vaccine, Spikevax bivalent Original/Omicron BA.1, mRNA-1283, BioNTech - Pfizer COVID-19 vaccine, COMIRNATY intramuscular injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lvrna009.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LVRNA009 — Competitive Intelligence Brief

LVRNA009 (LVRNA009) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology/Oncology.

phase 3 mRNA vaccine Immunology/Oncology Biologic Live · refreshed every 30 min

Target snapshot

LVRNA009 (LVRNA009) — AIM Vaccine Co., Ltd.. LVRNA009 is an mRNA vaccine designed to stimulate immune responses against specific disease targets through encoded antigen expression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LVRNA009 TARGET	LVRNA009	AIM Vaccine Co., Ltd.	phase 3	mRNA vaccine
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1283	mRNA-1283	ModernaTX, Inc.	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)
BioNTech - Pfizer COVID-19 vaccine	BioNTech - Pfizer COVID-19 vaccine	University of Birmingham	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LVRNA009 — Competitive Intelligence Brief. https://druglandscape.com/ci/lvrna009. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab